Definium Therapeutics, Inc. DFTX
Set alert
33.33 USD +0.86 +2.65%
As of Nov 3, 3:00 PM ET
32.73 Day range 34.62
10.47 52-week range 49.70
- YTD
- +148.92%
- 1 year
- +171.20%
- Open
- 32.99
- Prev close
- 32.47
- Mkt cap
- 4.48B
- Vol
- 1.06M
- Avg vol
- 2.18M
- EPS
- -3.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 32.73
- High
- 34.62
- Forward P/E
- -16.73
- Beta
- 2.21
- Short ratio
- 4.32
- Inst. own
- 96.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 37.77
- 200-d avg
- 29.60
- 1y target
- 72.56
15m chart
Built from the cached five-day intraday bars.
Signals (37)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 1:40 PM | 1 hour ago |
| SMA: Bullish | Nov 3, 1:10 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 11:40 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 9:40 AM | 5 hours ago |
| SMA: Bullish | Nov 3, 9:40 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 1 day ago |
| MACD: Buy Signal | Nov 2, 2:55 PM | 1 day ago |
| RSI: Oversold | Nov 2, 2:25 PM | 1 day ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 1 day ago |
| RSI: Oversold | Nov 2, 10:40 AM | 1 day ago |
| SMA: Bearish | Nov 2, 10:10 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:55 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 3:25 PM | 4 days ago |
| RSI: Oversold | Oct 30, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 4 days ago |
| RSI: Oversold | Oct 30, 2:10 PM | 4 days ago |
| RSI: Oversold | Oct 30, 12:10 PM | 4 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 4 days ago |
Newest 20 of 37.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 72.56 +117.7% upside
Now 33.33
- Target (low)
- 55.00
- Target (mean)
- 72.56
- Target (high)
- 91.00
Ratings (0m) 19 19 buy · 0 hold · 0 sell
- Strong buy5
- Buy14
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 19
- 1 month ago 18
- 2 months ago 18
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56065 | -0.70 – -0.45 | -0.78 | +28.1% | 0 | 0.0% | 14 |
| Next quarter | -0.53494 | -0.74 – -0.42 | -0.50 | -7.0% | 0 | 0.0% | 14 |
| Current year | -3.19 | -3.59 – -2.93 | -2.06 | -54.7% | 0 | 0.0% | 15 |
| Next year | -1.94 | -4.16 – 0.05 | -3.19 | +39.1% | 29.32M | 0.0% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Initiated | — | Overweight |
| Sep 15, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 15, 2026 | Baird | Maintained | Outperform | Outperform |
| Sep 14, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 14, 2026 | Needham | Reiterated | Buy | Buy |
| Sep 11, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 18, 2026 | B of A Securities | Initiated | — | Buy |
| Aug 14, 2026 | Maxim Group | Maintained | Buy | Buy |
| Aug 13, 2026 | Jones Trading | Maintained | Buy | Buy |
| Aug 13, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 13, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 13, 2026 | Baird | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Needham | Maintained | Buy | Buy |
| Aug 7, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 27, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jul 24, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 8, 2026 | Stifel | Maintained | Buy | Buy |
| Jun 30, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 24, 2026 | Jones Trading | Maintained | Buy | Buy |
| Jun 23, 2026 | Baird | Maintained | Outperform | Outperform |
| Jun 23, 2026 | Needham | Maintained | Buy | Buy |
| Jun 22, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Jun 22, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 16, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 8, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 22, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Apr 17, 2026 | Stifel | Initiated | — | Buy |
| Apr 16, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 10, 2026 | Piper Sandler | Initiated | — | Overweight |
